Moderna takes on a low-risk pact with CAR-T player Autolus for mRNA-based cancer drugs

Moderna’s Covid-19 vaccine has transformed the once-backwater biotech into one of the most highly valued drugmakers in the world in the span of a year. But what does the future hold for Moderna’s star turn? A small-scale discovery pact could offer a clue.

So Moderna will hold exclusive rights to...

Click to view original post